Completed PHASE2 INTERVENTIONAL 1-arm NCT02128828

Effect of Cenicriviroc on HIV Neurocognitive Impairment

H020: Single-Arm Open Label, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)

Sponsor: Tobira Therapeutics, Inc.

Conditions AIDS Dementia Complex HIV-1-Associated Cognitive Motor Complex Human Immunodeficiency Virus

Interventions cenicriviroc

Updated 10 times since 2017 Last updated: Aug 10, 2020 Started: Apr 30, 2014 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on AIDS Dementia Complex and HIV-1-Associated Cognitive Motor Complex, this trial is completed. The trial is conducted by Tobira Therapeutics, Inc. and has accumulated 10 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE2
Apr 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tobira Therapeutics, Inc.
University of Hawaii

Data source: University of Hawaii

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Honolulu, United States